Doctors Paint Rosy Picture of Dementia Drugs, Video Study of Clinic Talks Reveals

When a memory clinic doctor sits down with a patient newly diagnosed with dementia and explains what medication can do, the words chosen in those few minutes may shape whether the patient starts treatment, how faithfully they take it, and how well they understand what the drug is actually doing inside their brain. A new study from researchers at Leeds Beckett University, the University of Sheffield, Hull York Medical School, the University of York, the University of Exeter and Bradford District Care Trust has now captured those conversations as they really happen, and the picture that emerges is one of striking inconsistency. Published in BMC Health Services Research, the analysis of twenty-nine video-recorded memory assessment clinic consultations across two English NHS Trusts found that while clinicians broadly agreed on the basics of what to say, the way benefits and side effects were framed varied considerably from one consultation to the next, in ways the authors warn could directly influence patient outcomes.

The research team, led by Sarah Jane Smith of the Centre for Dementia Research at Leeds Beckett University, recorded consultations involving ten clinicians, twenty-nine patients and thirty-two relatives or supporters. This is a technically demanding kind of study to pull off. Recording real clinical encounters requires ethical approval, patient consent and careful handling of sensitive moments in people’s lives, and the study was approved by the National Research Ethics Service committee for Yorkshire and The Humber in March 2021, with adaptations for verbal and audio-recorded consent during the COVID-19 pandemic. Once recorded, the consultations were subjected to content analysis, a systematic method in which researchers code the talk against predefined categories to identify patterns in what is communicated, how often, and in what form. The approach allows researchers to move beyond anecdote and quantify precisely how treatment information is being delivered in routine practice.

The most consistent finding concerned how benefits were presented. In twenty-six of the twenty-nine consultations, clinicians framed the purpose of dementia medication as symptom management, and within that framing the dominant emphasis was on memory and cognition. That makes clinical sense, because the pharmacological treatments available for dementia, such as the cholinesterase inhibitors commonly prescribed for Alzheimer’s disease, are licensed to treat symptoms rather than to halt the underlying neurodegenerative disease. Yet the consistency ended there. In only thirteen of the twenty-nine consultations did clinicians explicitly state that the treatment was not curative, meaning that in more than half of the encounters patients may have left the room without a clear verbal statement that the drug could not stop or reverse their condition.

More surprising still was the language used to describe what the drugs might achieve beyond symptoms. In roughly one third of consultations, clinicians at some point suggested that treatment might be disease modifying, a claim that overstates the established evidence base for currently licensed dementia medications. Around half of the consultations referred to symptom reduction or delay. The researchers characterise this overall pattern as positive framing of treatment benefits, and the technical concern underlying it is well recognised in health communication research: when clinicians use leading or optimistic language about a therapy’s effects, patients can develop expectations that outstrip what the evidence supports, which in turn complicates decisions about continuing or stopping medication when benefits fail to materialise.

Side effects, by contrast, were discussed almost universally, appearing in twenty-six of the twenty-nine consultations. But the manner of that discussion revealed its own patterns. Clinicians frequently deployed verbal qualifiers, small linguistic hedges that signal the certainty or likelihood of an effect, such as indicating that something happens only occasionally or might occur. Qualifiers are not inherently problematic; they are a natural way of conveying probability in everyday speech. The difficulty arises when they are applied inconsistently, because a patient hearing that a side effect is possible in one consultation and unlikely in another receives materially different information about the same drug.

Perhaps the most consequential finding was how side effects were characterised when they were raised. The study found that the side effect profile was commonly described in minimising terms, presented as not serious or downplayed relative to the potential benefits. For patients and families weighing whether to start a medication, this framing matters enormously. Nausea, loss of appetite, vivid dreams and other recognised effects of dementia drugs can be distressing enough to prompt discontinuation, and a patient who has been told the effects are minor may feel misled when they experience them. The authors also note that explicit discussions weighing risks against benefits, the kind of balanced deliberation that shared decision-making ideally requires, occurred in only half of the consultations.

There was at least one area where communication fell short in a more mechanical way. In thirteen consultations, clinicians explained how the treatments actually work, the mechanism of action, and in eight of those the explanation was delivered in a patient-friendly way. That means fewer than a third of all consultations included an accessible account of the drug’s mechanism. For a population in which cognitive impairment is the defining feature, understanding how a medication is supposed to act is not a luxury; it is foundational to adherence, to monitoring for effects, and to making sense of follow-up appointments where treatment continuation is decided.

The variability the researchers documented is not simply a matter of individual clinician style. Because the consultations took place across two NHS Trusts with ten different clinicians, the inconsistency suggests an absence of shared standards for how dementia treatment information should be conveyed. The authors respond with three concrete recommendations. First, clinicians should exercise caution about using leading language that frames benefits optimistically without evidential warrant, including suggestions that drugs may modify the disease. Second, communication about both benefits and side effects should be consistent and transparent, so that patients receive comparable information regardless of which clinician they see. Third, evidence-based patient decision aids should be employed where appropriate, giving patients structured, balanced written or visual support to complement the spoken consultation.

The stakes of getting this right are considerable. Decisions about whether to take dementia medication are made at a moment when patients and families are absorbing a life-changing diagnosis, and the study’s authors point out that these discussions have a direct impact on the decision to take treatments, on understanding of the medications, and on adherence over time. A patient who believes a drug will slow their disease may persist with it despite troublesome side effects and no perceived benefit; a patient who was never told the treatment is not curative may face that realisation later without clinical support. Communication in the consultation is, in effect, the first dose of the treatment.

The research, funded by the National Institute for Health and Research through its Research for Patient Benefit programme, was strengthened by involvement from a patient and public involvement panel at the Centre for Dementia at Leeds Beckett. Its publication comes at a moment of intense public interest in dementia therapeutics, as new disease-modifying therapies enter clinical discussions worldwide and the pressure on memory clinics to communicate complex evidence grows. What this study demonstrates is that the infrastructure for those conversations, the everyday language of benefit and risk exchanged between doctor and patient, remains uneven. Standardising it, the authors argue, through guidance and decision aids, is a practical and achievable step toward ensuring that every patient with dementia receives the same honest, balanced account of what treatment can and cannot do.

Subject of Research: How clinicians communicate the benefits and side effects of dementia medications to patients in memory assessment clinics

Article Title: How do doctors discuss dementia treatments with patients? Content analysis of the presentation of treatment information, benefits and side effects

Article References: Smith, S. J., Griffiths, A. W., Knapp, P., Dickinson, R., Dooley, J., Russell, G., & Kelley, R. (2026). How do doctors discuss dementia treatments with patients? Content analysis of the presentation of treatment information, benefits and side effects. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15657-x

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15657-x

Keywords: dementia, health communication, shared decision-making, pharmacotherapy, memory clinics, content analysis, side effects, patient outcomes, geriatric care, NHS, informed consent, clinical consultation